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knockout mice causes Purkinje cell death and ataxia
Abstract
PrP knockout mice with disruption of only the PrP-encoding region (Zürich I-type) remain healthy,
whereas mice with deletions extending upstream of the PrP-encoding exon (Nagasaki-type) suffer
Purkinje cell loss and ataxia, associated with ectopic expression of Doppel in brain, particularly in
Purkinje cells. The phenotype is abrogated by co-expression of full-length PrP. Doppel is 25% similar to
PrP, has the same globular fold, but lacks the flexible N-terminal tail. We now show that in Zürich
I-type PrP-null mice, expression of N-terminally truncated PrP targeted to Purkinje cells also leads to
Purkinje cell loss and ataxia, which are reversed by PrP. Doppel and truncated PrP probably cause
Purkinje cell degeneration by the same mechanism.
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PrP knockout mice with disruption of only the PrP-
encoding region (ZuÈrich I-type) remain healthy,
whereas mice with deletions extending upstream of the
PrP-encoding exon (Nagasaki-type) suffer Purkinje
cell loss and ataxia, associated with ectopic expression
of Doppel in brain, particularly in Purkinje cells. The
phenotype is abrogated by co-expression of full-length
PrP. Doppel is 25% similar to PrP, has the same
globular fold, but lacks the ¯exible N-terminal tail.
We now show that in ZuÈrich I-type PrP-null mice,
expression of N-terminally truncated PrP targeted to
Purkinje cells also leads to Purkinje cell loss and
ataxia, which are reversed by PrP. Doppel and trun-
cated PrP probably cause Purkinje cell degeneration
by the same mechanism.
Keywords: cerebellar syndrome/Doppel protein/L7
promoter/prion protein/Purkinje cell loss
Introduction
The prion protein (PrP) plays a central role in the
pathogenesis of transmissible spongiform encephalopa-
thies (TSEs) such as Creutzfeldt±Jakob disease (CJD) or
bovine spongiform encephalopathy (BSE) (Prusiner, 1996;
Weissmann et al., 1996; Prusiner et al., 1998; Weissmann,
1999). Mice devoid of PrP are resistant to scrapie and fail
to propagate prions (BuÈeler et al., 1993; Manson et al.,
1994b; Sailer et al., 1994; Sakaguchi et al., 1995);
introduction of PrP-encoding transgenes restores suscep-
tibility to the disease (Fischer et al., 1996). The cellular
form of the prion protein, PrPC, is encoded by a single-
copy gene (Basler et al., 1986). It is attached by a
glycosylphosphatidyl inositol (GPI) anchor to the outer
cell surface and is found mainly in the brain, at neuronal
synapses (Sales et al., 1998). PrPC comprises a globular
domain consisting of three a-helices, one short antiparallel
b-sheet and a single disul®de bond (Riek et al., 1996). The
N-terminal half of the molecule is highly ¯exible (Donne
et al., 1997; Riek et al., 1997).
Several PrP knockout mouse lines have been generated,
differing in the design of the gene disruption (reviewed in
Weissmann and Aguzzi, 1999). Two lines in which only
the PrP-coding sequence was disrupted (BuÈeler et al.,
1992; Manson et al., 1994a), to be referred to as `ZuÈrich
I-type' mice, developed normally and remained healthy,
showing only minor electrophysiological de®cits
(Collinge et al., 1994; Colling et al., 1996) and altered
circadian rhythm (Tobler et al., 1996). However, three
other lines with more extensive gene deletions, `Nagasaki-
type' PrP knockout mice, developed Purkinje cell loss
followed by ataxia (Sakaguchi et al., 1996; Moore et al.,
1999; Rossi et al., 2001). Because the ataxic phenotype
could be rescued by a PrP-encoding transgene, it originally
was concluded that the phenotype was due to the absence
of PrP (Sakaguchi et al., 1996; Nishida et al., 1999),
although the conclusion was incompatible with the earlier
reports (Weissmann, 1996).
It was found later that the ataxic phenotype of all three
Nagasaki-type lines is associated with ectopic expression
of the PrP-like protein Doppel (Dpl) in brain (Moore et al.,
1999; Li et al., 2000a; Rossi et al., 2001). Dpl is an
N-glycosylated, GPI-anchored protein (Lu et al., 2000;
Silverman et al., 2000), normally expressed in a variety of
tissues but not in postnatal brain (Moore et al., 1999; Li
et al., 2000b). Its physiological function is still unknown,
but its absence causes male sterility in mice (Behrens et al.,
2002). Dpl and PrP show ~25% sequence similarity
(Moore et al., 1999), and both comprise three a-helices
and one antiparallel b-sheet in a similar fold, with only
minor differences (Lu et al., 2000; Silverman et al., 2000;
Mo et al., 2001). Dpl is encoded by Prnd, located 16 kb
downstream of the Prnp gene (Moore et al., 1999). The
loss of the splice acceptor site of the PrP-encoding Prnp
exon 3, a consequence of the PrP gene deletion strategy in
Nagasaki-type mice, causes formation of chimeric tran-
scripts containing the ®rst two non-coding exons of the
Prnp locus linked to the Dpl-encoding Prnd exon. This
places Dpl expression under the control of the Prnp
promoter (Moore et al., 1999; Li et al., 2000a). The time to
onset of disease is inversely correlated with the expression
level of Dpl in the brain and is rescued by co-expression of
PrPC (Rossi et al., 2001). Thus, ectopic expression of Dpl
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in the absence of PrP, rather than the absence of PrPC in
itself, causes Purkinje cell loss in Nagasaki-type PrP
knockout mice. Moore et al. (2001) reported that trans-
genic Prnpo/o mice expressing Dpl ubiquitously in brain
developed severe ataxia associated with loss of both
granule and Purkinje cells. The age of onset was inversely
proportional to the level of Dpl expression, and 1-month-
old mice were already affected (Moore et al., 2001).
Introduction of a hamster PrP-encoding transgene resulted
in complete abrogation of the cerebellar syndrome in mice
expressing moderate levels, and partial abrogation in
animals expressing high levels of Dpl. Both unaltered
incubation times and pathology in brain tissue expressing
PrP and Dpl upon challenge with different prion strains
sustain the conclusion (Behrens et al., 2001) that Dpl is
unlikely to be involved in prion pathogeneses (Moore
et al., 2001; Tuzi et al., 2002).
We reported earlier that expression in PrP knockout
mice of PrP lacking the ¯exible N-terminal tail
(PrPD32±121 or PrPD32±134) gives rise to a dose-
dependent phenotype comprising ataxia and loss of
cerebellar granule cells, which is abrogated by co-expres-
sion of wild-type PrP (Shmerling et al., 1998). Shmerling
et al. proposed that the binding of PrP to a putative ligand
elicits a signal necessary for cell survival and that a
functional homologue of PrP supplies this function in its
absence. Expression of truncated PrP was postulated to
interfere with signalling by displacing the functional
homologue from the ligand without eliciting the survival
signal of PrP. PrP, in turn, because of its higher af®nity for
the ligand, would displace its truncated counterpart and
restore the signal (Shmerling et al., 1998).
Because the overall structure of Dpl is remarkably
similar to that of the globular domain of PrP lacking the
¯exible N-terminus, the mechanism of pathogenesis might
be the same in both ataxic syndromes (Moore et al., 1999;
Weissmann and Aguzzi, 1999). Why, however, should
truncated PrP cause degeneration of granule cells while
Dpl entails Purkinje cell loss if the mechanism is the same?
Perhaps it is because the `half-genomic' PrP vector used to
express the truncated PrP is inactive in Purkinje cells, but
very active in granule cells (Fischer et al., 1996; Chiesa
et al., 1998), whilst Dpl, under the control of the intact PrP
promoter, is strongly upregulated in Purkinje cells and
much less so in granule cells (Li et al., 2000a).
To test this hypothesis, we targeted truncated PrP
speci®cally to Purkinje cells of ZuÈrich I-type PrP knockout
mice to determine whether the resulting phenotype would
be the same as that of Nagasaki-type PrP knockout mice
with ectopic expression of Dpl, namely age-dependent
Purkinje cell loss followed by ataxia, suppressible by a
single wild-type PrP allele.
Results
Purkinje cell loss and ataxia in mice expressing
the truncated PrP under the control of the
L7 promoter
We expressed PrP devoid of residues 32±134
(PrPD32±134) under the control of the Purkinje cell-
speci®c L7 promoter (Oberdick et al., 1990) in ZuÈrich I
Prnpo/o mice (BuÈeler et al., 1992). Three transgenic lines,
TgF32, TgF37 and TgF13, were generated and analysed
Table I. ZuÈrich I PrP knockout mouse lines expressing truncated PrP (PrPD32±134) under the control of the Purkinje cell-speci®c L7 promoter
Name of the linea Genotype Transgene
copy numberb
Age at onset of
ataxia (weeks)c
Mice
analysed
TgF32 Prnpo/o, Tg L7-DPrP/± 130 9 14
TgF37 Prnpo/o, Tg L7-DPrP/± 120 9 21
TgF13 Prnpo/o, Tg L7-DPrP/± 60 11 10
TgF13/Prnpo/+ Prnpo/+, Tg L7-DPrP/± n.d. >49 8
TgF13/Tga20 Prnpo/o, Tg L7-DPrP/, Tga20/± n.d. >70 11
aThe full designations of the lines are Prnptm1-Tg(PrPD134)332 Zbz for TgF32, Prnptm1-Tg(PrPD134)337 Zbz for TgF37, and B6D2F1-Tg(PrPD134)13
for TgF13.
bTransgenic copy numbers were estimated relative to standards by quantitative PCR using primers SIG and Mut217 (Shmerling et al., 1998). As
standards, mouse DNA containing 30 and 40 copies of the transgene cluster PrPD32±80 obtained from D11 and D12 mice were used, respectively
(Fischer et al., 1996). Because TgF13 mice showed the highest expression level of Purkinje cell-speci®c PrP and the most uniform labelling, all
complementation and time course experiments were carried out with this line.
cAverage age of mice when the phenotype was present in 50% of the mice analysed. Earliest onset and 100% morbidity were different for each line,
as shown in Figure 1.
n.d., not done.
Fig. 1. Age at onset of ataxic syndrome in mice expressing the trun-
cated PrP (PrPD32±134) under the control of the Purkinje cell-speci®c
L7 promoter. Hemizygous mice (L7-DPrP/±) of the lines TgF13 (n = 10),
TgF32 (n = 14) and Tg37 (n = 21) were assessed at 2-week intervals
for behavioural abnormalities, such as reduced exploratory activities,
trembling gait and ataxia. Mice displaying these abnormalities were
scored as affected. This syndrome was present in 50% of mice analysed
by ~9 and 11 weeks of age, depending on the line (Table I).
Introduction of a single wild-type allele (Prnp+) or a transgenic cluster
(Tga20) into the TgF13 line abrogated the ataxic phenotype in F1 off-
spring (TgF13,Prnp+/o; n = 8) and (TgF13,Tga20/±,Prnpo/o; n = 11),
respectively.
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(Table I; Figure 1). Truncated PrP was detectable only in
Purkinje cells, as judged by immunohistochemistry for PrP
(Figure 2). Within the Purkinje cells, truncated PrP is
highly expressed in cell bodies, axons and dendrites, as
shown in 3-week-old TgF13 mice (Figures 2 and 3). Mice
hemizygous for the transgene cluster on a Prnpo/o back-
ground showed the ®rst signs of behavioural abnormal-
ities, such as reduced exploratory activities and mild
trembling gait, at ~2 months. Mice displaying these
abnormalities were scored as affected (ataxic syndrome)
(Figure 1). The ataxic syndrome was present in 50% of
analysed mice by ~9±11 weeks, depending on the line
(Table I). Ataxia and trembling gait increased over time,
and footprint analysis revealed a similar pattern to that
described for the Nagasaki-type ZuÈrich II PrP knockout
mice (Rossi et al., 2001). After ~1 year, the general poor
condition of the mice precluded further maintenance.
The TgF13 line was selected for further analysis,
because it was the earliest to reach 100% morbidity
(Figure 1). Moreover, TgF13 mice had the highest level of
Purkinje cell-speci®c expression of the truncated PrP, as
judged by immunohistochemistry for PrP (data not
shown), and virtually all Purkinje cells were uniformly
labelled by immunostaining for PrP (Figures 2 and 3). We
analysed cerebellar sections of TgF13 mice for histo-
pathological changes before and after onset of symptoms
(Figure 2). At 3 weeks of age, there was marginal Purkinje
cell loss associated with slight gliosis in the molecular
layer, while the granular cell layer was normal. At
14 weeks, when behavioural abnormalities were present
in ~80% of the mice (Figure 1), there was severe focal and
moderate overall Purkinje cell loss accompanied by
astrogliosis in the molecular layer (Figure 2). Purkinje
cell bodies varied focally in shape and size, and some were
negative for calbindin, a speci®c Purkinje cell marker.
Degeneration progressed over the following months with
severe Purkinje cell loss and gliosis in the molecular layer
followed by shrinkage of the molecular layer and granule
cell loss. At 25 weeks, 3 months after onset of symptoms,
the number of Purkinje cell bodies and their dendrites in
the molecular layer was dramatically reduced (Figures 2
and 4A) and astrogliosis was evident in both molecular and
granule cell layers. At 49 weeks, Purkinje cells had
virtually disappeared; the very few remaining Purkinje
cells still expressed the (truncated) PrP both in soma and
dendrites (Figure 2). Shrinkage of the molecular layer was
striking and gliosis was prominent. There was neither
Purkinje cell loss nor glial ®brillary acidic protein (GFAP)
immunoreactivity in age-matched Prnpo/o and Prnpo/+
mice (Figure 2), indicating that the age-dependent
Purkinje cell loss in the transgenic mice was due to
L7-speci®c expression of truncated PrP, rather than to the
Fig. 2. Time course of Purkinje cell degeneration in ZuÈrich I Prnpo/o mice expressing truncated PrP (PrPD32±134) under the control of the Purkinje
cell-speci®c L7 promoter. Immunostaining for calbindin (top row), PrP (middle row) and GFAP (lower row) of sections through cerebella of L7-DPrP
mice (TgF13) are shown. Sections were immunostained for PrP using R340 and TSA ampli®cation as described in Materials and methods. GFAP and
calbindin were visualized as described in Materials and methods. Three-week-old mice show normal cerebellar structure with weak gliosis. Truncated
PrP is highly expressed in Purkinje cell bodies, axons and dendrites, but not in granule cells. After onset of ataxia, 14-week-old mice present with
Purkinje cell loss and moderate gliosis in the molecular layer. At 25 weeks, mice show an extended Purkinje cell loss associated with moderate gliosis.
In 49-week-old mice, there is an almost complete Purkinje cell loss, shrinkage of the molecular layer, decrease of granular cells and intense gliosis; a
single, remaining Purkinje cell is PrP positive. Age-matched controls (Prnpo/o, Prnpo/+) show an intact Purkinje cell layer and no gliosis.
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absence of PrP. The phenotype of the L7-DPrP mice was
thus similar to that of the three Nagasaki-type PrP
knockout lines exhibiting upregulation of Dpl (Sakaguchi
et al., 1996; Moore et al., 1999; Rossi et al., 2001). In
ZuÈrich II PrP knockout mice, which are of the Nagasaki-
type, there was an average Purkinje cell loss of 40% at
30 weeks, and at 40 weeks 50% of the mice were ataxic
(Rossi et al., 2001). As in the case of L7-DPrP mice, Dpl-
induced Purkinje cell loss progressed over several months
and exceeded 80% after 63 weeks (Rossi et al., 2001).
Purkinje cell loss was also accompanied by cerebellar
astrogliosis (Atarashi et al., 2001; Rossi et al., 2001).
Abrogation of the pathogenic effect of truncated
PrP by a Prnp wild-type allele
We next examined whether co-expression of PrP could
rescue the phenotype as described for the Nagasaki-type
mice (Nishida et al., 1999; Rossi et al., 2001). TgF13 mice
(expressing L7-DPrP) were crossed with C57BL/6 mice,
and the resulting transgenic TgF13/±,Prnpo/+ mice were
assessed by their home cage behaviour for 1 year. Intro-
duction of the wild-type PrP allele did not downregulate the
expression of the truncated PrP in the Purkinje cells
(Figure 3). As shown in Figure 1, all eight transgenic
TgF13/±,Prnpo/+ mice analysed remained healthy for
>11 months. Cerebella of transgenic TgF13/±,Prnpo/+
mice were analysed for Purkinje cell loss at 25 weeks,
35 weeks and 1 year of age. No obvious reduction in the
number of Purkinje cells (Figure 4A) and no astrogliosis
(data not shown) were observed at 25 weeks of age, when
severe Purkinje cell loss and reduction of the molecular
layer were evident in the absence of a wild-type PrP allele.
At 35 weeks, there was a slight to moderate loss of Purkinje
cells with a few reactive Bergman glia cells, but no
astrogliosis in the molecular layer (data not shown).
Cerebella of 1-year-old healthy TgF13/±,Prnpo/+ mice
showed moderate Purkinje cell loss that was not found in
aged-matched Prnpo/+ mice (data not shown). In contrast,
Purkinje cells were completely absent and shrinkage of the
molecular layer was evident in 1-year-old ataxic transgenic
TgF13/±,Prnpo/o mice. There was a moderate loss of granule
cells, possibly due to disappearance of their Purkinje cell
targets, which was not found in Prnpo/+ controls (data not
shown). Thus, a wild-type PrP allele fully abrogated the
clinical manifestations elicited by L7-DPrP transgene
expression, although it did not completely suppress
Purkinje cell loss. Similarly, mice carrying one wild-type
PrP and one ZuÈrich II PrP allele showed no clinical
symptoms after as long as 100 weeks (Rossi et al., 2001).
Abrogation of the pathogenic effect of truncated
PrP by a Tga20 allele cluster expressing PrP in
brain with the exception of Purkinje cells
It was suggested earlier that PrP did not have to be
expressed in Purkinje cells in order to rescue the Dpl-
induced phenotype in ZuÈrich II mice (Rossi et al., 2001)
because PrP expressed under the direction of the `half-
genomic' PrP promoter (the Tga20 gene cluster) abrogated
Fig. 3. Immunostaining for PrP in Purkinje cells of wild-type, PrP knockout and L7-DPrP transgenic mice. Cerebellar sections were immunostained
for PrP using R340 and TSA ampli®cation as described in Materials and methods. The truncated PrP is strongly overexpressed in Purkinje cell bodies,
axons and dendrites of 3-week-old TgF13 mice (TgF13,Prnpo/o) in comparison with a faint staining in wild-type controls (Prnp+/+). No background
staining was found in the same area of PrP knockout mice (Prnpo/o) processed in parallel with all sections shown. Introduction of a single wild-type
Prnp+ allele in transgenic mice completely abrogated the ataxic phenotype. L7-DPrP transgene expression is not decreased in 3-week-old mice
(TgF13/±,Prnpo/+) or older mice (data not shown). It is striking that the pathogenic effect of the truncated PrP at levels several times higher than PrP
levels in wild-type mice is completely abolished by a single Prnp+ allele, suggesting a highly speci®c effect of wild-type PrP in counteracting the
L7-DPrP-induced cell degeneration.
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the clinical phenotype, although this promoter is active in
brain in general but not in Purkinje cells (Fischer et al.,
1996; Rossi et al., 2001). We bred the Tga20 allele cluster
into transgenic TgF13/±,Prnpo/o mice. Of 11 double
transgenic mice (TgF13/±,Tga20/±,Prnpo/o) analysed,
none developed behavioural abnormalities within 1 year
(Figure 1). At 20 weeks, there was complete suppression
of Purkinje cell degeneration in the cerebella of those mice
(Figure 4B). However, we found moderate Purkinje cell
loss in an 85-week-old double-transgenic mouse, as
compared with slight Purkinje cell loss, without astro-
gliosis, in a 78-week-old control mouse hemizygous for
the Tga20 allele cluster. We cannot exclude the possibility
that levels of PrP undetectable by our immunohistochem-
ical analysis suf®ced to ensure Purkinje cell survival.
Alternatively, perhaps PrP expressed at the synapses of
neighbouring cells can supply the protective effect or can
be physically transferred, as shown for PrP in vitro (Liu
et al., 2002) and for other GPI-linked proteins in vitro
(Anderson et al., 1996) and in vivo (Kooyman et al., 1995).
In Purkinje cells of wild-type mice, PrP is found at pre-
and postsynaptic spines (Haeberle et al., 2000). In the
cerebellum, PrP is also found on other neuronal cells, such
as Golgi type II, stellate and basket cells, and to a lesser
extent on granule cells (Laine et al., 2001; Liu et al., 2001;
Ford et al., 2002).
Discussion
This project aimed to determine whether expression of
N-terminally truncated PrP (PrPD32±134) targeted specif-
ically to Purkinje cells of ZuÈrich I PrP knockout mice
resulted in the same phenotype observed in three lines of
Nagasaki-type PrP knockout mice with upregulation of
Dpl in brain, namely ataxia and Purkinje cell degeneration,
which was abrogated by PrP.
Indeed, transgenic mice overexpressing truncated PrP in
Purkinje cells under the control of the L7 promoter
developed ataxia and Purkinje cell degeneration similar to
that of Nagasaki-type mice, but 8 months earlier than the
latter (Rossi et al., 2001). Because onset of ataxia in
Nagasaki-type PrP knockout mice is inversely correlated
with the expression levels of Dpl in the brain (Rossi et al.,
2001), we assume that the earlier onset of the phenotype in
Fig. 4. Purkinje cell degeneration in L7-DPrP transgenic mice is mitigated by co-expression of PrP. Cerebellar sections were immunostained for
calbindin, a marker for Purkinje cells. Prnpo/o and wild-type (Prnp+/+) controls show normal Purkinje cell layers at 40 and 43 weeks, respectively.
(A) L7-DPrP mice (TgF13/±,Prnpo/o) at 25 weeks presented with severe loss of Purkinje cell dendrites and cell bodies, associated with a reduction of
the molecular layer. In the presence of a wild-type allele (TgF13/±,Prnpo/+), Purkinje cell loss was completely abrogated at 25 weeks and strongly miti-
gated at 35 weeks. (B) Introduction of the Tga20 transgene cluster into L7-DPrP mice (TgF13/±,Tga20/±,Prnpo/o) resulted in PrP expression in brain,
except in the Purkinje cells; in these mice, Purkinje cell loss was practically abrogated at 20 weeks and mitigated at 85 weeks of age. There was also a
slight Purkinje cell loss in the age-matched controls (Tga20/±,Prnpo/o).
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our L7-DPrP transgenic lines is due to the high expression
level of the truncated PrP. Introduction of a wild-type PrP
allele into L7-DPrP transgenic Prnpo/o mice rescued the
phenotype completely: there was no Purkinje cell loss in
L7-DPrP transgenic Prnpo/+ at 6 months of age and only a
slight reduction of Purkinje cells in mice older than
8 months. Similarly, Purkinje cell degeneration caused by
ectopic expression of Dpl in a Nagasaki-type line ZuÈrich II
was suppressed in the presence of a wild-type Prnp or
Tga20 allele for >20 months, and there was also a mild
Purkinje cell loss in older mice expressing the Tga20 allele
(Rossi et al., 2001). Moreover, Dpl-induced Purkinje cell
loss in Nagasaki-type lines is accompanied by astrogliosis
(Sakaguchi et al., 1996; Rossi et al., 2001). Astrogliosis
was present in the cerebellum, but also in the white matter
of the forebrain. Because there was no evidence of
neuronal damage other than Purkinje cell degeneration, the
reason for activation of glia and microglia in the forebrain
of Nagasaki PrP-null mice remains unclear (Atarashi et al.,
2001). In the cerebellum, astrogliosis occurred several
months before the onset of Purkinje cell degeneration
(Atarashi et al., 2001). Likewise, astrogliosis is already
apparent in 3-week-old L7-DPrP transgenic Prnpo/o mice,
when the Purkinje cell layer appears still normal.
Astrogliosis is a prominent histopathological feature in
Dpl- and L7-DPrP-expressing PrP null mice, which is
completely absent in the presence of wild-type PrP. Taken
together, the phenotype caused by the L7-controlled
overexpression of the truncated PrP (PrPD32±134) and
its rescue by wild-type PrP strongly suggests that L7-DPrP
transgenic Prnpo/o mice closely mimic Nagasaki-type PrP
knockout mice with ectopic expression of Dpl.
The ataxic syndrome is due speci®cally to overexpres-
sion of truncated PrP and not just overexpression of PrP in
general, because several fold overexpression of the
truncated PrP in Purkinje cells in L7-DPrP transgenic
mice is completely abrogated by a Prnpo/+ allele contrib-
uting an additional amount of PrP. Our ®ndings support
the proposal that the truncated PrP and Dpl cause cell
death by the same mechanism, perhaps by interfering with
a signalling pathway essential for maintenance of cell
viability, which is normally activated by PrP, or, in its
absence, by a conjectural functional homologue
(Shmerling et al., 1998). Alternatively, truncated PrP and
Dpl might activate an apoptotic pathway that normally is
kept quiescent by PrP (or a functional homologue). It is of
interest in this context that stimulation of differentiated
neuronal cells by a monoclonal antibody to PrP leads to
activation of the tyrosine kinase Fyn, which has been
interpreted as pointing to a signalling function for PrP
(Mouillet-Richard et al., 2000). The ®ndings that neuronal
cultures of Nagasaki-type PrP knockout mice, which
presumably express Dpl, undergo apoptosis more readily
than wild-type cultures (Kuwahara et al., 1999) and that
PrP protects against Bax-mediated apoptosis (Bounhar
et al., 2001) suggest an anti-apoptotic role for PrP.
However, other or additional functions have been pro-
posed for PrP, such as cell±cell interactions (Rieger et al.,
1997), copper transport (Pauly and Harris, 1998; Brown,
1999) and resistance to oxidative stress (Brown et al.,
1999; Wong et al., 2000). Wong et al. (2001) proposed
that Dpl expression exacerbates oxidative damage that is
antagonistic to the protective function of wild-type PrP. A
deeper understanding of the normal function of PrP and
Dpl is required to elucidate the processes leading to cell
death by ectopic expression of Dpl or of truncated PrP
lacking the ¯exible tail of PrP.
Materials and methods
Generation of transgenic mice
The expression vector L7-PrPD32±134 encoding PrPD32±134 under
control of the L7 promoter was generated by blunt end ligation of the
KpnI±NarI fragment of plasmid PRP123.F (Shmerling et al., 1998) into
the blunted BamHI site of plasmid L7-pGEM3 (Oberdick et al., 1990).
The vector was digested with HindIII and EcoRI, puri®ed and injected
into fertilized oocytes from Prnpo/o mice as described (Shmerling et al.,
1998). Line F13 resulted from injection into fertilized oocytes from
Prnp+/+ (F1 of C57BL/6 3 DBA/2) mice. Founders were identi®ed by
Southern blot analysis of BamHI-digested tail DNA using the PrP open
reading frame probe and mated to Prnpo/o ZuÈrich I mice (BuÈeler et al.,
1992) to establish transgenic lines with a Prnpo/o background.
Histopathology and immunohistochemistry
Animals were culled, and their brains were removed and ®xed for at least
24 h in 4% paraformaldehyde in phosphate-buffered saline (PBS). Fixed
samples were embedded in paraf®n, sectioned at 1±2 mm and processed
for haematoxylin/eosin (H&E) staining, GFAP, calbindin or PrP
immunostaining, as described (Rossi et al., 2001). Brie¯y, GFAP
immunostaining was performed by using anti-GFAP rabbit antiserum
(1:300; Dako Glostrup, Denmark). For staining of Purkinje cells, sections
were stained with anti-calbindin monoclonal antibody (1:5000; Sigma
Chemical Company, St Louis, MO), and visualized by a biotinylated
rabbit anti-mouse antibody (1:200; Dako) according to the manufactur-
ers' instructions. PrP was detected on microwave-treated sections using
polyclonal anti-rabbit antibody R340 (1:200), and visualization was
performed with the Tyramide Signal Ampli®cation (TSA) kit (NENÔ;
Life Science, Boston, MA) according to the manufacturers' instructions.
Behavioural assessment
Mice were analysed at 2-week intervals for behavioural abnormalities,
such as reduced exploratory activities, trembling gait and ataxia.
Footprints of mice were performed as described (Rossi et al., 2001).
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